Triamcinolone associated with few side effects

Article

Intravitreal triamcinolone acetonide (IVTA) for the treatment of steroid-responsive disorders of the posterior segment is associated with a low incidence of serious vision-threatening adverse events.

Intravitreal triamcinolone acetonide (IVTA) for the treatment of steroid-responsive disorders of the posterior segment is associated with a low incidence of serious vision-threatening adverse events, according to a report published in the January issue of Retina.

Daniel Roth of the Robert Wood Johnson Medical School, New Jersey, USA and colleagues retrospectively reviewed the medical records of 784 patients (929 consecutive eyes) who had received one or more IVTA injections for a steroid-responsive posterior segment disorder.

The most common adverse event occurring within three months of the initial injection was steroid-related ocular hypertension, with intraocular pressure spikes of >21 mmHg in 21% of eyes and >25 mmHg in 11% of eyes. Ocular inflammation was observed in six eyes (0.6%) and three eyes (0.3%) had corneal epithelial defects thought to be related to pretreatment with povidone-iodine solution. No eyes had culture-positive infectious endophthalmitis.

When administered under sterile conditions, concluded the authors, IVTA is associated with a low incidence of serious adverse events.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.